Insights from 2023 ASCO® Annual Meeting


 

ASCO® 2023 Insights: "Results From the Pivotal Phase 2b HERIZON-BTC-01 Study - Zanidatamab in Previously-Treated HER2‑Amplified Biliary Tract Cancer"

91 views
June 21, 2023
Comments 0
Login to view comments. Click here to Login